214 related articles for article (PubMed ID: 25333816)
21. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.
Seki N; Toh U; Sayers TJ; Fujii T; Miyagi M; Akagi Y; Kusukawa J; Kage M; Shirouzu K; Yamana H
Mol Cancer Ther; 2010 Jun; 9(6):1842-51. PubMed ID: 20515944
[TBL] [Abstract][Full Text] [Related]
23. Telomere-homologous G-rich oligonucleotides sensitize human ovarian cancer cells to TRAIL-induced growth inhibition and apoptosis.
Sarkar S; Faller DV
Nucleic Acid Ther; 2013 Jun; 23(3):167-74. PubMed ID: 23634944
[TBL] [Abstract][Full Text] [Related]
24. Targeting of miR-20a against CFLAR to potentiate TRAIL-induced apoptotic sensitivity in HepG2 cells.
Wang Y; Zhao YR; Zhang AY; Ma J; Wang ZZ; Zhang X
Eur Rev Med Pharmacol Sci; 2017 May; 21(9):2087-2097. PubMed ID: 28537677
[TBL] [Abstract][Full Text] [Related]
25. Human embryonic and induced pluripotent stem cells express TRAIL receptors and can be sensitized to TRAIL-induced apoptosis.
Vinarsky V; Krivanek J; Rankel L; Nahacka Z; Barta T; Jaros J; Andera L; Hampl A
Stem Cells Dev; 2013 Nov; 22(22):2964-74. PubMed ID: 23806100
[TBL] [Abstract][Full Text] [Related]
26. The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation.
Fan S; Li Y; Yue P; Khuri FR; Sun SY
Neoplasia; 2010 Apr; 12(4):346-56. PubMed ID: 20360945
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
Chen KF; Yeh PY; Hsu C; Hsu CH; Lu YS; Hsieh HP; Chen PJ; Cheng AL
J Biol Chem; 2009 Apr; 284(17):11121-33. PubMed ID: 19261616
[TBL] [Abstract][Full Text] [Related]
28. Targeting eIF4A using rocaglate CR‑1‑31B sensitizes gallbladder cancer cells to TRAIL‑mediated apoptosis through the translational downregulation of c‑FLIP.
Cao Y; He Y; Yang L; Luan Z
Oncol Rep; 2021 Jan; 45(1):230-238. PubMed ID: 33416145
[TBL] [Abstract][Full Text] [Related]
29. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
[TBL] [Abstract][Full Text] [Related]
30. Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression.
Wang C; Qi R; Li N; Wang Z; An H; Zhang Q; Yu Y; Cao X
J Biol Chem; 2009 Jun; 284(24):16183-16190. PubMed ID: 19376776
[TBL] [Abstract][Full Text] [Related]
31. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1.
Wirth T; Kühnel F; Fleischmann-Mundt B; Woller N; Djojosubroto M; Rudolph KL; Manns M; Zender L; Kubicka S
Cancer Res; 2005 Aug; 65(16):7393-402. PubMed ID: 16103092
[TBL] [Abstract][Full Text] [Related]
32. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression.
Syed V; Mukherjee K; Godoy-Tundidor S; Ho SM
J Cell Biochem; 2007 Oct; 102(2):442-52. PubMed ID: 17393432
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of c-FLIP by RNAi enhances sensitivity of the human osteogenic sarcoma cell line U2OS to TRAIL-induced apoptosis.
Zhang YP; Kong QH; Huang Y; Wang GL; Chang KJ
Asian Pac J Cancer Prev; 2015; 16(6):2251-6. PubMed ID: 25824746
[TBL] [Abstract][Full Text] [Related]
34. Adenovirus-mediated transfection of caspase-8 sensitizes hepatocellular carcinoma to TRAIL- and chemotherapeutic agent-induced cell death.
Yamaguchi Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Nakano T
Biochim Biophys Acta; 2006 Aug; 1763(8):844-53. PubMed ID: 16750275
[TBL] [Abstract][Full Text] [Related]
35. Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP.
Zhang T; Wang X; He D; Jin X; Guo P
Anticancer Drugs; 2014 Sep; 25(8):887-97. PubMed ID: 24714080
[TBL] [Abstract][Full Text] [Related]
36. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.
Pathil A; Armeanu S; Venturelli S; Mascagni P; Weiss TS; Gregor M; Lauer UM; Bitzer M
Hepatology; 2006 Mar; 43(3):425-34. PubMed ID: 16583461
[TBL] [Abstract][Full Text] [Related]
37. Galectin-1 Modulates the Survival and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Sensitivity in Human Hepatocellular Carcinoma Cells.
Li J; Sun RR; Yu ZJ; Liang H; Shen S; Kan Q
Cancer Biother Radiopharm; 2015 Oct; 30(8):336-41. PubMed ID: 26348206
[TBL] [Abstract][Full Text] [Related]
38. Downregulation of SNAIL sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis by regulating the NF-κB pathway.
Wan Z; Pan H; Liu S; Zhu J; Qi W; Fu K; Zhao T; Liang J
Oncol Rep; 2015 Mar; 33(3):1560-6. PubMed ID: 25607597
[TBL] [Abstract][Full Text] [Related]
39. Carnosic acid sensitized TRAIL-mediated apoptosis through down-regulation of c-FLIP and Bcl-2 expression at the post translational levels and CHOP-dependent up-regulation of DR5, Bim, and PUMA expression in human carcinoma caki cells.
Jung KJ; Min KJ; Bae JH; Kwon TK
Oncotarget; 2015 Jan; 6(3):1556-68. PubMed ID: 25596735
[TBL] [Abstract][Full Text] [Related]
40. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells.
Llobet D; Eritja N; Encinas M; Llecha N; Yeramian A; Pallares J; Sorolla A; Gonzalez-Tallada FJ; Matias-Guiu X; Dolcet X
Oncogene; 2008 Apr; 27(18):2513-24. PubMed ID: 17982483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
